Cases
Real challenges. Real impact.
Proof from regulated healthcare environments, based on commercial accountability, not advisory frameworks.
Strategic partnerships · Strategic accounts
€10M+
DSM Biomedical
International co-development and supply partnerships within medical devices and biomaterials, with commercial opportunities exceeding €10 million.
- Situation
- DSM Biomedical develops and supplies biomaterials for medical applications. Growth there does not come from one-off sales, but from long-term co-development and supply relationships with MedTech and pharma companies.
- Role
- Global Business & Commercial Development Manager (2018–2021), responsible for partnerships, licensing and strategic accounts, with EMEA as a key part of the scope.
- Result
- More than €10M in co-development opportunities built
- Development and supply relationships up to eight-figure value
- DSM Circle of Excellence 2019
Healthcare ventures
EU GMP
Stabican
Co-built an EU-GMP platform for analysis and formulation within a regulated pharmaceutical environment, from financing to first patient use.
- Situation
- Supplying into a regulated pharma environment requires an EU GMP foundation for analysis and formulation. That foundation still had to be built.
- Role
- Co-founder & Managing Director of Stabican (2017–2023).
- Result
- A platform for analysis and formulation, built from concept to real-world application
- EU GMP certification obtained in 2022
- In discussions with pharma companies about deploying the platform
Commercialization
Market access
Allergan
Market access, pricing and reimbursement for two business units: the conditions under which a product actually reaches the patient.
- Situation
- A product only reaches patients once reimbursement and adoption into care are in place. Market access therefore determines commercial success.
- Role
- Market Access, Pricing & Reimbursement Manager (2013–2015), for two business units.
- Result
- Developed pricing, reimbursement and value strategies for pharmaceutical and ophthalmology products, working with hospitals, payers and clinicians.
Commercialization
Value communication
International medical aesthetics company
- Situation
- Specialists, hospitals and nursing institutions choose a therapy not only on clinical value, but also on what the treatment yields them.
- Role
- Independent Business Consultant / Strategic Commercial Advisor (Q22), engagement directly for an international medical aesthetics company.
- Result
- Developed an approach for an international medical aesthetics company to show clients (specialists, hospitals, nursing institutions) how to declare the treatment as a DBC based on injected units, and what revenue this generates alongside the clinical value.
Contact
A commercial challenge in European healthcare?
Q22 works with MedTech, Pharma and Life Sciences organizations that need senior commercial capacity for commercialization, partnerships or European growth.